Bionik Laboratories Corp. BNKL
We take great care to ensure that the data presented and summarized in this overview for Bionik Laboratories Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BNKL
Top Purchases
Top Sells
About BNKL
Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Robots, which include a suite of robotic rehabilitation products; InMotion ARM, an evidence-based intelligent interactive rehabilitation technology that senses patient movements and limitations; InMotion ARM/HAND, which provides support for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion Connect platform that consists of a hardware device connected to the InMotion Robot, as well as a subscription to InMotion Connect Pulse. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts.
Insider Transactions at BNKL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 13
2023
|
Andre Jacques Auberton Herve Director |
BUY
Conversion of derivative security
|
Indirect |
186,111
+14.37%
|
$0
$0.6 P/Share
|
|
Jun 13
2023
|
Remi Gaston Dreyfus Director |
BUY
Conversion of derivative security
|
Indirect |
3,102,878
+38.69%
|
$0
$0.6 P/Share
|
|
Jun 09
2023
|
Andre Jacques Auberton Herve Director |
BUY
Open market or private purchase
|
Indirect |
650,000
+41.32%
|
$0
$0.6 P/Share
|
|
Jun 09
2023
|
Remi Gaston Dreyfus Director |
BUY
Open market or private purchase
|
Indirect |
180,555
+9.05%
|
$0
$0.6 P/Share
|
|
Jun 09
2023
|
Charles Matine Director |
BUY
Open market or private purchase
|
Direct |
180,555
+46.59%
|
$0
$0.6 P/Share
|
|
Mar 31
2022
|
Remi Gaston Dreyfus Director |
BUY
Conversion of derivative security
|
Indirect |
77,887
+4.6%
|
$700,983
$9.5 P/Share
|
|
Jul 15
2021
|
Andre Jacques Auberton Herve Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
59,378
+9.19%
|
$178,134
$3.38 P/Share
|
|
Jul 15
2021
|
Remi Gaston Dreyfus Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
120,759
+3.54%
|
-
|
|
Mar 29
2021
|
Remi Gaston Dreyfus Director |
BUY
Grant, award, or other acquisition
|
Indirect |
61,256
+3.98%
|
-
|
|
Mar 29
2021
|
Peter Gerald Malone Director |
BUY
Open market or private purchase
|
Direct |
26,430
+50.0%
|
-
|
|
Mar 29
2021
|
Charles Matine Director |
BUY
Open market or private purchase
|
Direct |
26,430
+50.0%
|
-
|
|
Mar 29
2021
|
Audrey Thevenon Director |
BUY
Open market or private purchase
|
Direct |
26,430
+50.0%
|
-
|
|
Mar 29
2021
|
Joseph R Martin Director |
BUY
Open market or private purchase
|
Direct |
26,430
+50.0%
|
-
|
|
Mar 26
2021
|
Remi Gaston Dreyfus Director |
BUY
Open market or private purchase
|
Indirect |
135,560
+8.72%
|
-
|
|
Mar 26
2021
|
Andre Jacques Auberton Herve Director |
BUY
Open market or private purchase
|
Direct |
95,149
+50.0%
|
-
|